

- 1 Foster C.S., Kothari S., Anesi S.D. et al. The Ocular Immunology and Uveitis Foundation preferred practice patterns of uveitis management. *Surv Ophthalmol.* 2016, 10.1016/j.survophthal.2015.07.001 [PubMed]
- 2 Jabs D.A., Rosenbaum J.T., Foster C.S. et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. *Am. J. Ophthalmol.*, no 130(4), 2000 Oct., p. 492-513
- 3 Braun J., Baraliakos X., Listing J., Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. *Arthritis Rheum.* 2005, 10.1002/art.21197 [PubMed]
- 4 Jaffe G.J., Dick A.D., Brézín A.P. et al. Adalimumab in patients with active noninfectious uveitis. *N. Engl. J. Med.* 2016, 10.1056/NEJMoa1509852 [PubMed]
- 5 Callanan D.G., Jaffe G.J., Martin D.F., Pearson P.A., Comstock T.L. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. *Arch. Ophthalmol.*, no 126(9), 2008 Sep., p. 1191-1201